Postmortem studies previously suggested, and in vivo amyloid imaging studies have now unambiguously confirmed that individuals with a similar burden of amyloid-beta (A|3) in their brains can be cognitively normal, have Mild Cognitive Impairment (MCI) or Alzheimer's disease (AD). Thus, it seems highly likely that there are modulators that can accelerate or retard the effects of AB on the brain. Postmortem studies also have suggested that the presence and amount of vascular pathology in the brain is a likely modulator. The overall concept is that the presence of vascular pathology in the brain establishes a vulnerable state in which the deposition of AB much more quickly leads to the onset and progression of cognitive impairment and the clinical syndromes of MCI and AD. The modulators of the transition from normal cognition to MCI will be explored in Project 4. In this project (Project 5) we will explore the modulators of the transition from MCI to clinical AD. The fundamental hypothesis is that the brain, like the rest of the body, tries to maintain homeostasis in the face of injury (induced, in this case, by AP). We propose that one of the most important mechanisms for successful homeostasis and compensation is modulation of cerebral blood flow and even subclinical cerebrovascular disease can significantly accelerate the adverse effects of AB deposition. We propose to test this hypothesis by using PiB PET to measure the effect of AB deposition (the toxin) on three main outcomes: 1) cerebral metabolism (FDG PET);2) brain volume (structural MRI);and 3) cognition (neuropsychological testing). We also will measure potential AB modulators such as cerebral and systemic subclinical vascular disease and cerebral blood flow (perfusion MRI). We further propose that cognitive vulnerability accumulates along with markers of vascular disease with aging and in very elderly individuals, the relative importance of vascular and AB burden may be different than in younger persons. Thus, we will make use of a younger group of MCI subjects that have been studied for 24 months or more in the previous project period of this Program Project and an existing older group (>83 years) who have participated in a seven-year study of gingko biloba in aging and who have also been studied once with PiB prior to this study.

Public Health Relevance

It is clear that levels of fibrillar AB deposition alone cannot fully account for the variability in cognitive status across the normal aging-MCI-AD spectrum. While efforts at reducing AP accumulation are essential, understanding the modulators of the effect of AB may be equally important and lead to a further appreciation of the importance of cerebrovascular and cardiovascular health with aging. Identifying individuals particularly prone to damaging the effects of AB should help select the best candidates for future anti-amyloid therapies.

National Institute of Health (NIH)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Perez, Sylvia E; He, Bin; Nadeem, Muhammad et al. (2015) Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease. Biol Psychiatry 77:693-703
Klunk, William E; Koeppe, Robert A; Price, Julie C et al. (2015) The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11:1-15.e1-4
Pivtoraiko, Violetta N; Abrahamson, Eric E; Leurgans, Sue E et al. (2015) Cortical pyroglutamate amyloid-? levels and cognitive decline in Alzheimer's disease. Neurobiol Aging 36:9-Dec
McDade, Eric; Kim, Albert; James, Jeffrey et al. (2014) Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease. Neurology 83:710-7
Cohen, Ann D; Klunk, William E (2014) Early detection of Alzheimer's disease using PiB and FDG PET. Neurobiol Dis 72 Pt A:117-22
Hong, Young T; Veenith, Tonny; Dewar, Deborah et al. (2014) Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. JAMA Neurol 71:23-31
Lopez, Oscar L; Klunk, William E; Mathis, Chester et al. (2014) Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. Neurology 83:1804-11
Hughes, Timothy M; Kuller, Lewis H; Barinas-Mitchell, Emma J M et al. (2014) Arterial stiffness and ?-amyloid progression in nondemented elderly adults. JAMA Neurol 71:562-8
Gandy, Sam; Ikonomovic, Milos D; Mitsis, Effie et al. (2014) Chronic traumatic encephalopathy: clinical-biomarker correlations and current concepts in pathogenesis. Mol Neurodegener 9:37
Mizukami, Katsuyoshi; Abrahamson, Eric E; Mi, Zhiping et al. (2014) Immunohistochemical analysis of ubiquilin-1 in the human hippocampus: association with neurofibrillary tangle pathology. Neuropathology 34:11-8

Showing the most recent 10 out of 59 publications